B.O.S.S. Retirement Advisors LLC Invests $221,000 in Abbott Laboratories (NYSE:ABT)

B.O.S.S. Retirement Advisors LLC purchased a new stake in shares of Abbott Laboratories (NYSE:ABT) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,956 shares of the healthcare product maker’s stock, valued at approximately $221,000.

A number of other large investors also recently modified their holdings of the company. Toth Financial Advisory Corp raised its holdings in Abbott Laboratories by 8.1% in the fourth quarter. Toth Financial Advisory Corp now owns 103,700 shares of the healthcare product maker’s stock valued at $11,730,000 after buying an additional 7,814 shares during the period. CFS Investment Advisory Services LLC raised its stake in shares of Abbott Laboratories by 3.1% in the 4th quarter. CFS Investment Advisory Services LLC now owns 18,469 shares of the healthcare product maker’s stock valued at $2,089,000 after acquiring an additional 558 shares during the period. Grimes & Company Inc. boosted its position in Abbott Laboratories by 0.3% during the 4th quarter. Grimes & Company Inc. now owns 58,124 shares of the healthcare product maker’s stock worth $6,574,000 after purchasing an additional 179 shares during the period. Linden Thomas Advisory Services LLC increased its holdings in Abbott Laboratories by 8.6% in the 4th quarter. Linden Thomas Advisory Services LLC now owns 31,308 shares of the healthcare product maker’s stock valued at $3,541,000 after purchasing an additional 2,488 shares in the last quarter. Finally, Cyndeo Wealth Partners LLC lifted its stake in shares of Abbott Laboratories by 1.2% during the fourth quarter. Cyndeo Wealth Partners LLC now owns 178,939 shares of the healthcare product maker’s stock worth $20,240,000 after purchasing an additional 2,179 shares in the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Abbott Laboratories Trading Up 1.5 %

Shares of NYSE:ABT opened at $125.12 on Friday. The firm has a market cap of $217.01 billion, a P/E ratio of 16.36, a P/E/G ratio of 2.51 and a beta of 0.73. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. Abbott Laboratories has a twelve month low of $99.71 and a twelve month high of $125.67. The company has a 50 day moving average of $115.26 and a 200-day moving average of $113.31.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share for the quarter, hitting the consensus estimate of $1.34. The firm had revenue of $10.97 billion for the quarter, compared to analysts’ expectations of $11,029,400 billion. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The company’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same period in the previous year, the company posted $1.19 EPS. As a group, analysts anticipate that Abbott Laboratories will post 5.15 earnings per share for the current fiscal year.

Abbott Laboratories Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be issued a dividend of $0.59 per share. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.55. This represents a $2.36 annualized dividend and a dividend yield of 1.89%. The ex-dividend date of this dividend is Wednesday, January 15th. Abbott Laboratories’s payout ratio is currently 30.85%.

Analysts Set New Price Targets

Several brokerages recently commented on ABT. Piper Sandler raised their target price on Abbott Laboratories from $131.00 to $133.00 and gave the company an “overweight” rating in a report on Thursday, October 17th. Raymond James restated a “buy” rating and issued a $129.00 target price (up from $122.00) on shares of Abbott Laboratories in a research note on Monday, October 14th. Jefferies Financial Group lifted their price target on shares of Abbott Laboratories from $120.00 to $125.00 and gave the stock a “hold” rating in a research note on Thursday, October 17th. Stifel Nicolaus upped their price objective on shares of Abbott Laboratories from $130.00 to $135.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Wells Fargo & Company boosted their price target on Abbott Laboratories from $133.00 to $136.00 and gave the stock an “overweight” rating in a research note on Thursday. Four research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $132.50.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.